AI assistant
Sending…
MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2023
Jan 19, 2023
30608_dirs_2023-01-18_0f5a237e-5ef8-4999-80e1-bfd36b183975.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2023-01-16
Reporting Person: Waltermire Robert E. (Senior VP, Chief Pharma Dev.)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-16 | Common Stock | A | 5667 | $0.00 | Acquired | 5667 | Direct |
Footnotes
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
More from MADRIGAL PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Annual Report
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Feb 24
Annual Report
2026
Feb 19
Regulatory Filings
2026
Feb 19
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 26